Hyperlipidemia and insu- lin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35 43. S4.5.5-19. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected par- ticipants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45: 111 9. S4.5.5-20. Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population- based cohort study. Arthritis Rheum. 2007;56:820 30. S4.5.5-21. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482 7. S4.5.5-22. Ronda N, Favari E, Borghi MO, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythema- tosus. Ann Rheum Dis. 2014;73:609 15. S4.5.5-23. Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430 8. 5. STATIN SAFETY AND STATIN- ASSOCIATED SIDE EFFECTS S5-1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. S5-2. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discus- sion for atherosclerotic cardiovascular disease prevention: impor- tance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65:1361 8. S5-3. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96 103. S5-4. Gupta A, Thompson D, Whitehouse A, et al. 